These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 21432601

  • 1. Drug policy and treatment bias due to the dopamine-deficit theory of child attention-deficit hyperactivity disorder.
    Rastmanesh R.
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):149-57. PubMed ID: 21432601
    [Abstract] [Full Text] [Related]

  • 2. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [Abstract] [Full Text] [Related]

  • 3. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA, Faraone SV.
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).
    Oades RD.
    Prog Brain Res; 2008 Apr; 172():543-65. PubMed ID: 18772050
    [Abstract] [Full Text] [Related]

  • 11. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
    Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK, Reske SN, Fegert JM, Mottaghy FM.
    Neuroimage; 2008 Jul 01; 41(3):718-27. PubMed ID: 18424180
    [Abstract] [Full Text] [Related]

  • 12. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis.
    Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD.
    Neuropsychol Rev; 2007 Mar 01; 17(1):39-59. PubMed ID: 17318414
    [Abstract] [Full Text] [Related]

  • 13. What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications.
    Levy F.
    Aust N Z J Psychiatry; 2007 Jan 01; 41(1):10-6. PubMed ID: 17464676
    [Abstract] [Full Text] [Related]

  • 14. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
    Volkow ND, Wang GJ, Fowler JS, Ding YS.
    Biol Psychiatry; 2005 Jun 01; 57(11):1410-5. PubMed ID: 15950015
    [Abstract] [Full Text] [Related]

  • 15. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 2005 Jun 01; 16(2):1-37. PubMed ID: 10868163
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder.
    Stahl SM.
    J Clin Psychiatry; 2010 Jan 01; 71(1):12-3. PubMed ID: 20129003
    [No Abstract] [Full Text] [Related]

  • 17. Attention deficit and hyperactivity disorder: review of genetic association studies.
    Galili-Weisstub E, Segman RH.
    Isr J Psychiatry Relat Sci; 2003 Jan 01; 40(1):57-66. PubMed ID: 12817670
    [Abstract] [Full Text] [Related]

  • 18. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.
    Pliszka SR.
    Biol Psychiatry; 2005 Jun 01; 57(11):1385-90. PubMed ID: 15950012
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.